06/10/2026
A woman and a man can have the same creatinine level, yet she is already further into chronic kidney disease than he is. Lower muscle mass means ๐๐๐ฎ๐ป๐ฑ๐ฎ๐ฟ๐ฑ ๐ฐ๐ฟ๐ฒ๐ฎ๐๐ถ๐ป๐ถ๐ป๐ฒ ๐๐ฒ๐๐๐ ๐ฟ๐ผ๐๐๐ถ๐ป๐ฒ๐น๐ ๐๐ป๐ฑ๐ฒ๐ฟ๐ฒ๐๐๐ถ๐บ๐ฎ๐๐ฒ ๐ธ๐ถ๐ฑ๐ป๐ฒ๐ ๐ฑ๐๐๐ณ๐๐ป๐ฐ๐๐ถ๐ผ๐ป ๐ถ๐ป ๐๐ผ๐บ๐ฒ๐ป, ๐ฑ๐ฒ๐น๐ฎ๐๐ถ๐ป๐ด ๐ฟ๐ฒ๐ณ๐ฒ๐ฟ๐ฟ๐ฎ๐น๐ ๐ฎ๐ป๐ฑ ๐๐๐ฟ๐๐ฒ๐ถ๐น๐น๐ฎ๐ป๐ฐ๐ฒ ๐น๐ผ๐ป๐ด ๐ฎ๐ณ๐๐ฒ๐ฟ ๐ฟ๐ถ๐๐ธ ๐ต๐ฎ๐ ๐๐ฒ๐ ๐ถ๐ป.
The gap doesn't stop at diagnosis. Women are less likely to start dialysis, less likely to receive a transplant, and when they do start treatment, it's often later and less adequately dosed. In some low- and middle-income countries, the male-to-female transplant ratio exceeds 10 to 1. Guideline-recommended, ๐ธ๐ถ๐ฑ๐ป๐ฒ๐-๐ฝ๐ฟ๐ผ๐๐ฒ๐ฐ๐๐ถ๐๐ฒ ๐บ๐ฒ๐ฑ๐ถ๐ฐ๐ฎ๐๐ถ๐ผ๐ป๐ ๐ฎ๐ฟ๐ฒ ๐ฝ๐ฟ๐ฒ๐๐ฐ๐ฟ๐ถ๐ฏ๐ฒ๐ฑ ๐๐ผ ๐๐ผ๐บ๐ฒ๐ป ๐น๐ฒ๐๐ ๐ผ๐ณ๐๐ฒ๐ป ๐ฎ๐ป๐ฑ ๐ฑ๐๐ฟ๐ถ๐ป๐ด ๐ฟ๐ฒ๐ฝ๐ฟ๐ผ๐ฑ๐๐ฐ๐๐ถ๐๐ฒ ๐๐ฒ๐ฎ๐ฟ๐, ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ถ๐ฒ๐ ๐ฎ๐ฟ๐ฒ ๐ณ๐ฟ๐ฒ๐พ๐๐ฒ๐ป๐๐น๐ ๐๐ถ๐๐ต๐ต๐ฒ๐น๐ฑ ๐ฎ๐น๐๐ผ๐ด๐ฒ๐๐ต๐ฒ๐ฟ over pregnancy concerns, even when alternatives aren't offered in their place.
Underlying all of this is a research gap: women remain underrepresented in kidney trials, leaving real uncertainty about optimal dosing and outcomes for female patients.
Earlier, equitable detection wasn't a women's issue; it's a system issue. Closing it starts with recognizing where the standard approach falls short.
